131 related articles for article (PubMed ID: 16797377)
1. Protein kinase C-beta as a therapeutic target in breast cancer.
Sledge GW; Gökmen-Polar Y
Semin Oncol; 2006 Jun; 33(3 Suppl 9):S15-8. PubMed ID: 16797377
[TBL] [Abstract][Full Text] [Related]
2. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
Herbst RS; Oh Y; Wagle A; Lahn M
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
[TBL] [Abstract][Full Text] [Related]
3. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
[TBL] [Abstract][Full Text] [Related]
4. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
5. PKC inhibition and diabetic microvascular complications.
Clarke M; Dodson PM
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease.
Kelly DJ; Edgley AJ; Zhang Y; Thai K; Tan SM; Cox AJ; Advani A; Connelly KA; Whiteside CI; Gilbert RE
Nephrol Dial Transplant; 2009 Jun; 24(6):1782-90. PubMed ID: 19155535
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
8. [Role of PKCbeta in the malignant tumors and enzastaurin, a PKCbeta inhibitor].
Li XY; Chen XG
Yao Xue Xue Bao; 2009 May; 44(5):449-55. PubMed ID: 19618717
[TBL] [Abstract][Full Text] [Related]
9. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
10. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
[TBL] [Abstract][Full Text] [Related]
11. Enzastaurin.
Ma S; Rosen ST
Curr Opin Oncol; 2007 Nov; 19(6):590-5. PubMed ID: 17906457
[TBL] [Abstract][Full Text] [Related]
12. Exploitation of protein kinase C: a useful target for cancer therapy.
Ali AS; Ali S; El-Rayes BF; Philip PA; Sarkar FH
Cancer Treat Rev; 2009 Feb; 35(1):1-8. PubMed ID: 18778896
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Green LJ; Marder P; Ray C; Cook CA; Jaken S; Musib LC; Herbst RS; Carducci M; Britten CD; Basche M; Eckhardt SG; Thornton D
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3408-15. PubMed ID: 16740765
[TBL] [Abstract][Full Text] [Related]
14. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase C-zeta activation markedly enhances beta-cell proliferation: an essential role in growth factor mediated beta-cell mitogenesis.
Vasavada RC; Wang L; Fujinaka Y; Takane KK; Rosa TC; Mellado-Gil JM; Friedman PA; Garcia-Ocaña A
Diabetes; 2007 Nov; 56(11):2732-43. PubMed ID: 17686945
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
Kim W; Yoon JH; Kim JR; Jang IJ; Bang YJ; Kim YJ; Lee HS
Cancer Chemother Pharmacol; 2009 Aug; 64(3):497-507. PubMed ID: 19096848
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
Roy V; Perez EA
Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C-beta inhibition for diabetic kidney disease.
Tuttle KR
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S70-4. PubMed ID: 18977550
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
[TBL] [Abstract][Full Text] [Related]
20. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
Casellini CM; Barlow PM; Rice AL; Casey M; Simmons K; Pittenger G; Bastyr EJ; Wolka AM; Vinik AI
Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]